BioAI benchmarks may be leaking seen molecules into supposedly unseen tests
DeryaTR_ · x · 2026-07-22
A benchmark problem may be holding back BioAI progress: according to the quoted thread, the standard “exams” used for small-molecule activity prediction often are not truly out-of-sample.
The key claim is that many drug-discovery benchmarks contain molecules the models have effectively already seen, which makes them a poor test of generalization. The thread argues that better evaluation design is necessary if BioAI is going to advance meaningfully.
More from Research
- AI slop is already clogging PR review and weakening the credit system behind science — rbhar90 · 2026-07-27
- ICML 2026 oral paper replication scores stay middling after a stricter re-scoring — profjamesevans · 2026-07-27
- Long-running agents will need immutable event logs, this thread argues — sebpaquet · 2026-07-27
- Seed IQ navigates Doom II, prompting questions about benchmarks beyond ARC-AGI — Fit_Transition8824 · 2026-07-27
- Agentic Data Science in Practice: Agents Write Code but Answer Wrong Questions — hugobowne · 2026-07-27
- A concise canon of foundational papers in ML, systems, NLP, speech, and audio — deliprao · 2026-07-27